{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:32:41Z","timestamp":1792672361295,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG079859-01"],"award-info":[{"award-number":["R01AG079859-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG066429-02"],"award-info":[{"award-number":["R01AG066429-02"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG054199-02"],"award-info":[{"award-number":["RF1AG054199-02"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067763-01"],"award-info":[{"award-number":["R01AG067763-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG072719-01"],"award-info":[{"award-number":["R01AG072719-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG082704"],"award-info":[{"award-number":["RF1 AG082704"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG054672"],"award-info":[{"award-number":["R01AG054672"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tau tubulin kinase-1 (TTBK1), a neuron-specific tau kinase, is highly expressed in the entorhinal cortex and hippocampal regions, where early tau pathology evolves in Alzheimer\u2019s disease (AD). The protein expression level of TTBK1 is elevated in the cortex brain tissues with AD patients compared to the control subjects. We therefore hypothesized that antisense oligonucleotide (ASO) based targeting <jats:italic>Ttbk1<\/jats:italic> could prevent the accumulation of phosphorylated tau, thereby delaying the development of tau pathology in AD. Here we show that in vivo administration of ASO targeting mouse <jats:italic>Ttbk1<\/jats:italic> (ASO-<jats:italic>Ttbk1<\/jats:italic>) specifically suppressed the expression of <jats:italic>Ttbk1<\/jats:italic> without affecting <jats:italic>Ttbk2<\/jats:italic> expression in the temporal cortex of PS19 tau transgenic mice. Central administration of ASO-<jats:italic>Ttbk1<\/jats:italic> in PS19 mice significantly reduced the expression level of representative phosphor-tau epitopes relevant to AD at 8\u00a0weeks post-dose, including pT231, pT181, and pS396 in the sarkosyl soluble and insoluble fractions isolated from hippocampal tissues as determined by ELISA and pS422 in soluble fractions as determined by western blotting. Immunofluorescence demonstrated that ASO-<jats:italic>Ttbk1<\/jats:italic> significantly reduced pS422 phosphorylated tau intensity in mossy fibers region of the dentate gyrus in PS19 mice. RNA-sequence analysis of the temporal cortex tissue revealed significant enrichment of interferon-gamma and complement pathways and increased expression of antigen presenting molecules (Cd86, Cd74, and H2-Aa) in PS19 mice treated with ASO-<jats:italic>Ttbk1<\/jats:italic>, suggesting its potential effect on microglial phenotype although neurotoxic effect was absent. These data  suggest that TTBK1 is an attractive therapeutic target to suppress TTBK1 without compromising TTBK2 expression and pathological tau phosphorylation in the early stages of AD.<\/jats:p>","DOI":"10.1186\/s40478-023-01661-3","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:28:07Z","timestamp":1697686087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice"],"prefix":"10.1186","volume":"11","author":[{"given":"Kayo","family":"Yukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Yamamoto-Mcguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Cafaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Kamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneya","family":"Ikezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-730X","authenticated-orcid":false,"given":"Seiko","family":"Ikezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"1661_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","volume":"24","author":"VM-Y Lee","year":"2001","unstructured":"Lee VM-Y, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121\u20131159. https:\/\/doi.org\/10.1146\/annurev.neuro.24.1.1121","journal-title":"Annu Rev Neurosci"},{"key":"1661_CR2","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1523\/jneurosci.16-14-04491.1996","volume":"16","author":"T G\u00f3mez-Isla","year":"1996","unstructured":"G\u00f3mez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer\u2019s disease. J Neurosci 16:4491\u20134500. https:\/\/doi.org\/10.1523\/jneurosci.16-14-04491.1996","journal-title":"J Neurosci"},{"key":"1661_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259. https:\/\/doi.org\/10.1007\/BF00308809","journal-title":"Acta Neuropathol"},{"key":"1661_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1471-4159.2006.04059.x","volume":"98","author":"S Sato","year":"2006","unstructured":"Sato S, Cerny RL, Buescher JL, Ikezu T (2006) Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem 98:1573\u20131584. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04059.x","journal-title":"J Neurochem"},{"key":"1661_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bpa.12001","volume":"23","author":"H Lund","year":"2013","unstructured":"Lund H, Cowburn RF, Gustafsson E, Str\u00f6mberg K, Svensson A, Dahllund L, Malinowsky D, Sunnemark D (2013) Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer\u2019s disease brain. Brain Pathol 23:378\u2013389. https:\/\/doi.org\/10.1111\/bpa.12001","journal-title":"Brain Pathol"},{"key":"1661_CR6","first-page":"1","volume":"4","author":"S Ikezu","year":"2020","unstructured":"Ikezu S, Dixie KLI, Koro L, Watanabe T, Kaibuchi K (2020) Tau-tublin kinase 1 and amyloid-beta peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models. Acta Neuropathol Commun 4:1\u201316","journal-title":"Acta Neuropathol Commun"},{"key":"1661_CR7","doi-asserted-by":"publisher","first-page":"14511","DOI":"10.1523\/JNEUROSCI.3417-08.2008","volume":"28","author":"S Sato","year":"2008","unstructured":"Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan RJ, Schlautman JD, Ciborowski P, Ikezu T (2008) Spatial learning impairment, enhanced CDK5\/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci 28:14511\u201314521. https:\/\/doi.org\/10.1523\/JNEUROSCI.3417-08.2008","journal-title":"J Neurosci"},{"key":"1661_CR8","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1096\/fj.09-150144","volume":"24","author":"J Xu","year":"2010","unstructured":"Xu J, Sato S, Okuyama S, Swan RJ, Jacobsen MT, Strunk E, Ikezu T (2010) Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice. FASEB J 24:2904\u20132915. https:\/\/doi.org\/10.1096\/fj.09-150144","journal-title":"FASEB J"},{"key":"1661_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000106875","volume":"7","author":"T Kimura","year":"1996","unstructured":"Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T (1996) Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dement Geriatr Cogn Disord 7:177\u2013181. https:\/\/doi.org\/10.1159\/000106875","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1661_CR10","doi-asserted-by":"publisher","first-page":"23331","DOI":"10.1074\/jbc.M113.463984","volume":"288","author":"A Cavallini","year":"2013","unstructured":"Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C, Moore R, Calley J, Ramachandran D, Poidinger M et al (2013) An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with alzheimer disease. J Biol Chem 288:23331\u201323347. https:\/\/doi.org\/10.1074\/jbc.M113.463984","journal-title":"J Biol Chem"},{"key":"1661_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12749","author":"CM Moloney","year":"2022","unstructured":"Moloney CM, Labuzan SA, Crook JE, Siddiqui H, Castanedes-Casey M, Lachner C, Petersen RC, Duara R, Graff-Radford NR, Dickson DW et al (2022) Phosphorylated tau sites that are elevated in Alzheimer\u2019s disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.12749","journal-title":"Alzheimer\u2019s Dement"},{"key":"1661_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00401-020-02251-6","volume":"141","author":"L Arag\u00e3o Gomes","year":"2021","unstructured":"Arag\u00e3o Gomes L, Uytterhoeven V, Lopez-Sanmartin D, Tom\u00e9 SO, Tousseyn T, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Verstreken P, Thal DR (2021) Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. Acta Neuropathol. 141:173\u2013192. https:\/\/doi.org\/10.1007\/s00401-020-02251-6","journal-title":"Acta Neuropathol."},{"key":"1661_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neulet.2011.01.011","volume":"491","author":"NN Yu","year":"2011","unstructured":"Yu NN, Yu JT, Xiao JT, Zhang HW, Lu RC, Jiang H, Xing ZH, Tan L (2011) Tau-tubulin kinase-1 gene variants are associated with Alzheimer\u2019s disease in Han Chinese. Neurosci Lett 491:83\u201386. https:\/\/doi.org\/10.1016\/j.neulet.2011.01.011","journal-title":"Neurosci Lett"},{"key":"1661_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-2011-110794","volume":"27","author":"JL V\u00e1zquez-Higuera","year":"2011","unstructured":"V\u00e1zquez-Higuera JL, Mateo I, S\u00e1nchez-Juan P, Rodr\u00edguez-Rodr\u00edguez E, Pozueta A, Calero M, Dobato JL, Frank-Garc\u00eda A, Valdivieso F, Berciano J et al (2011) Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 27:291\u2013297. https:\/\/doi.org\/10.3233\/JAD-2011-110794","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1661_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","volume":"7","author":"LR Moore","year":"2017","unstructured":"Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, Hung G, Kordasiewicz HB, Paulson HL, McLoughlin HS (2017) Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models. Mol Ther Nucleic Acids 7:200\u2013210. https:\/\/doi.org\/10.1016\/j.omtn.2017.04.005","journal-title":"Mol Ther Nucleic Acids"},{"key":"1661_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TCC, Maeda J, Suhara T, Trojanowski JQ, Lee VMY (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337\u2013351. https:\/\/doi.org\/10.1016\/j.neuron.2007.01.010","journal-title":"Neuron"},{"key":"1661_CR17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1046\/j.1471-4159.2002.01241.x","volume":"83","author":"N Sahara","year":"2002","unstructured":"Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH (2002) Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem 83:1498\u20131508. https:\/\/doi.org\/10.1046\/j.1471-4159.2002.01241.x","journal-title":"J Neurochem"},{"key":"1661_CR18","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.2174\/138161209789649330","volume":"15","author":"G Cuny","year":"2009","unstructured":"Cuny G (2009) Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr Pharm Des 15:3919\u20133939. https:\/\/doi.org\/10.2174\/138161209789649330","journal-title":"Curr Pharm Des"},{"key":"1661_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.expneurol.2016.06.030","volume":"283","author":"CT Tiernan","year":"2016","unstructured":"Tiernan CT, Combs B, Cox K, Morfini G, Brady ST, Counts SE, Kanaan NM (2016) Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. Exp Neurol 283:318\u2013329. https:\/\/doi.org\/10.1016\/j.expneurol.2016.06.030","journal-title":"Exp Neurol"},{"key":"1661_CR20","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1523\/JNEUROSCI.4854-06.2007","volume":"27","author":"E Planel","year":"2007","unstructured":"Planel E, Richter KEG, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB et al (2007) Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 27:3090\u20133097. https:\/\/doi.org\/10.1523\/JNEUROSCI.4854-06.2007","journal-title":"J Neurosci"},{"key":"1661_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549:523\u2013527. https:\/\/doi.org\/10.1038\/nature24016","journal-title":"Nature"},{"key":"1661_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/brain\/awaa376","volume":"144","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N, Takamatsu-Yukawa K, Hu J, Wang Y, Hersh S et al (2021) Alzheimer\u2019s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain 144:288\u2013309. https:\/\/doi.org\/10.1093\/brain\/awaa376","journal-title":"Brain"},{"key":"1661_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","volume":"287","author":"R Kohnken","year":"2000","unstructured":"Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, Shen J, M\u00f6ller H-J, Davies P, Hampel H (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer\u2019s disease patients. Neurosci Lett 287:187\u2013190. https:\/\/doi.org\/10.1016\/S0304-3940(00)01178-2","journal-title":"Neurosci Lett"},{"key":"1661_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sj\u00f6gren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49\u201352. https:\/\/doi.org\/10.1016\/S0304-3940(00)01036-3","journal-title":"Neurosci Lett"},{"key":"1661_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O\u2019Loughlin E, Xu Y, Fanek Z et al (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47:566-581.e9. https:\/\/doi.org\/10.1016\/j.immuni.2017.08.008","journal-title":"Immunity"},{"key":"1661_CR26","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/ng.2007.43","volume":"39","author":"H Houlden","year":"2007","unstructured":"Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, Worth P, Singleton AB, Hilton DA, Holton J, Revesz T et al (2007) Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 39:1434\u20131436. https:\/\/doi.org\/10.1038\/ng.2007.43","journal-title":"Nat Genet"},{"key":"1661_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1460-9568.2006.05226.x","volume":"25","author":"J-Z Wang","year":"2007","unstructured":"Wang J-Z, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59\u201368. https:\/\/doi.org\/10.1111\/j.1460-9568.2006.05226.x","journal-title":"Eur J Neurosci"},{"key":"1661_CR28","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1021\/acs.jmedchem.1c00382","volume":"64","author":"T Halkina","year":"2021","unstructured":"Halkina T, Henderson JL, Lin EY, Himmelbauer MK, Jones JH, Nevalainen M, Feng J, King K, Rooney M, Johnson JL et al (2021) Discovery of potent and brain-penetrant tau tubulin kinase 1 (TTBK1) inhibitors that lower tau phosphorylation in vivo. J Med Chem 64:6358\u20136380. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00382","journal-title":"J Med Chem"},{"key":"1661_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0228771","volume":"15","author":"GM Dillon","year":"2020","unstructured":"Dillon GM, Henderson JL, Bao C, Joyce JA, Calhoun M, Amaral B, King KW, Bajrami B, Rabah D (2020) Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites. PLoS ONE 15:1\u201322. https:\/\/doi.org\/10.1371\/journal.pone.0228771","journal-title":"PLoS ONE"},{"key":"1661_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1107\/S2053230X2000031X","volume":"76","author":"DJ Marcotte","year":"2020","unstructured":"Marcotte DJ, Spilker KA, Wen D, Hesson T, Patterson TA, Kumar PR, Chodaparambil JV (2020) The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor. Acta Crystallogr Sect F Struct Biol Commun 76:103\u2013108. https:\/\/doi.org\/10.1107\/S2053230X2000031X","journal-title":"Acta Crystallogr Sect F Struct Biol Commun"},{"key":"1661_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/07391102.2019.1590242","volume":"38","author":"S Jana","year":"2020","unstructured":"Jana S, Singh SK (2020) Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation. J Biomol Struct Dyn 38:886\u2013900. https:\/\/doi.org\/10.1080\/07391102.2019.1590242","journal-title":"J Biomol Struct Dyn"},{"key":"1661_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejmech.2018.10.030","volume":"161","author":"V Nozal","year":"2019","unstructured":"Nozal V, Martinez A (2019) Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. Eur J Med Chem 161:39\u201347. https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.030","journal-title":"Eur J Med Chem"},{"key":"1661_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.molcel.2017.08.009","volume":"67","author":"Y Shinohara","year":"2017","unstructured":"Shinohara Y, Koyama YM, Ukai-Tadenuma M, Hirokawa T, Kikuchi M, Yamada RG, Ukai H, Fujishima H, Umehara T, Tainaka K et al (2017) Temperature-sensitive substrate and product binding underlie temperature-compensated phosphorylation in the clock. Mol Cell 67:783-798.e20. https:\/\/doi.org\/10.1016\/j.molcel.2017.08.009","journal-title":"Mol Cell"},{"key":"1661_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1107\/S2053230X14000144","volume":"70","author":"SE Kiefer","year":"2014","unstructured":"Kiefer SE, Chang CJ, Kimura SR, Gao M, Xie D, Zhang Y, Zhang G, Gill MB, Mastalerz H, Thompson LA et al (2014) The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor. Acta Crystallogr Sect F Struct Biol Commun 70:173\u2013181. https:\/\/doi.org\/10.1107\/S2053230X14000144","journal-title":"Acta Crystallogr Sect F Struct Biol Commun"},{"key":"1661_CR35","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/cmdc.201300274","volume":"8","author":"Y Xue","year":"2013","unstructured":"Xue Y, Wan PT, Hillertz P, Schweikart F, Zhao Y, Wissler L, Dekker N (2013) X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors. ChemMedChem 8:1846\u20131854. https:\/\/doi.org\/10.1002\/cmdc.201300274","journal-title":"ChemMedChem"},{"key":"1661_CR36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.51166","author":"E Bowie","year":"2020","unstructured":"Bowie E, Goetz SC (2020) TTBK2 and primary cilia are essential for the connectivity and survival of cerebellar Purkinje neurons. Elife. https:\/\/doi.org\/10.7554\/eLife.51166","journal-title":"Elife"},{"key":"1661_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1471-4159.2006.03784.x","volume":"97","author":"AL Guillozet-Bongaarts","year":"2006","unstructured":"Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI (2006) Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: In vitro evidence and implications for tangle formation in vivo. J Neurochem 97:1005\u20131014. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03784.x","journal-title":"J Neurochem"},{"key":"1661_CR38","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.ajpath.2011.07.044","volume":"179","author":"L Vana","year":"2011","unstructured":"Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI (2011) Progression of tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer\u2019s disease. Am J Pathol 179:2533\u20132550. https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.044","journal-title":"Am J Pathol"},{"key":"1661_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2174\/156720512800492503","volume":"9","author":"N Zommer","year":"2012","unstructured":"Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9:397\u2013405. https:\/\/doi.org\/10.2174\/156720512800492503","journal-title":"Curr Alzheimer Res"},{"key":"1661_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10571-020-00875-6","volume":"41","author":"C Bao","year":"2021","unstructured":"Bao C, Bajrami B, Marcotte DJ, Chodaparambil JV, Kerns HM, Henderson J, Wei R, Gao B, Dillon GM (2021) Mechanisms of regulation and diverse activities of tau-tubulin kinase (TTBK) isoforms. Cell Mol Neurobiol 41:669\u2013685. https:\/\/doi.org\/10.1007\/s10571-020-00875-6","journal-title":"Cell Mol Neurobiol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01661-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:53:29Z","timestamp":1700495609000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01661-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01661-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures followed the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by Boston University Institutional Animal Care and Use Committee (IACUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.H. and F.K. are employed by Ionis Pharmaceuticals. T.I. consults Takeda. Otherwise, the authors declare no potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}